trabectedin
Sign in to saveTrabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer.
Article
11 sectionsContents
- Discovery and production
- Approvals and indications
- Soft tissue sarcoma
- Ovarian cancer and other
- Structure
- Biosynthesis
- Total synthesis
- Mechanism of action
- Society and culture
- Legal status
- References
Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer.
The most common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache.
Connections
Categories
Acetate estersAntineoplastic drugsBacterial alkaloidsBenzodioxolesDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrug has EMA linkDrugs developed by Johnson & JohnsonDrugs with non-standard legal statusECHA InfoCard ID from WikidataHydroxyarenesOrphan drugs